Sands Capital Life Sciences Pulse Fund III (DE), L.P. - 06 Feb 2026 SCHEDULE 13G Report for SpyGlass Pharma, Inc. Common Stock, $0.00001 par value per share

Filing Manager
Sands Capital Life Sciences Pulse Fund III (DE), L.P.
Reporting Manager
SANDS FRANK M.
Security
SpyGlass Pharma, Inc. Common Stock, $0.00001 par value per share
Shares outstanding
32,051,436 shares
Disclosed Ownership
2,500,012 shares
Ownership
7.8%
Form type
SCHEDULE 13G
Filing time
13 Feb 2026, 11:36:01 UTC
Date of event
06 Feb 2026
SEC
View on sec.gov

Reporting Managers (4)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Sands Capital Life Sciences Pulse Fund III (DE), L.P. 1.3% 420,797 0 420,797 /s/ Jonathan Goodman Jonathan Goodman, General Counsel of the GP of the GP of Sands Capital Life Sciences Pulse Fund III (DE), L.P.
Sands Capital Life Sciences Pulse Fund III-Holdings, L.P. 6.5% 2,079,215 0 2,079,215 /s/ Jonathan Goodman Jonathan Goodman, General Counsel of the GP of the GP of Sands Capital Life Sciences Pulse Fund III-Holdings, L.P.
Sands Capital Alternatives, LLC 1.3% 420,797 0 420,797 /s/ Jonathan Goodman Jonathan Goodman, General Counsel
SANDS FRANK M. 7.8% 2,500,012 0 2,500,012 /s/ Frank M. Sands Frank M. Sands